Adma Biologics (ADMA) Consolidated Net Income (2011 - 2025)

Adma Biologics has reported Consolidated Net Income for 13 years, with the latest figure at $49.4 million in Q4 2025.

• For the quarter ending Q4 2025, Consolidated Net Income fell 55.87% year-over-year to $49.4 million; the trailing twelve-month figure through Dec 2025 stood at $146.9 million (down 25.67% YoY), and the FY2025 full-year result was $146.9 million, down 25.67% from the prior year.
• Consolidated Net Income for Q4 2025 stood at $49.4 million, up from $36.4 million in the prior quarter.
• The five-year high for Consolidated Net Income was $111.9 million in Q4 2024, with the low at -$18.8 million in Q2 2021.
• Historically, Consolidated Net Income has averaged $10.7 million across 5 years, with a median of -$1.9 million in 2023.
• Annual changes were most pronounced in 2024 — Consolidated Net Income surged 1299.96% — and 2025, when it sank 55.87%.
• Adma Biologics' Consolidated Net Income stood at -$16.5 million in 2021, then grew by 28.55% to -$11.8 million in 2022, then jumped by 189.84% to $10.6 million in 2023, then soared by 956.22% to $111.9 million in 2024, then slumped by 55.87% to $49.4 million in 2025.
• The last three Consolidated Net Income figures came in at $49.4 million (Q4 2025), $36.4 million (Q3 2025), and $34.2 million (Q2 2025), per Business Quant data.